Lupin Bioresearch Center gets zero USFDA observation after successful inspection, assessment
Written By : Ruchika Sharma
Published On 2025-11-08 09:38 GMT | Update On 2025-11-08 09:38 GMT
Advertisement
Mumbai: Lupin Limited, a Global pharma major, has announced that the United States Food and Drug Administration (U.S. FDA) has completed an onsite clinical inspection from November 3 to November 6, 2025, at its Bioresearch Centre in Pune that concluded with zero 483 observations.
A bio-analytical Remote Regulatory Assessment was also conducted from October 30 to November 7, 2025, and concluded with no observations.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.